title: [Efficacy and safety of dapoxetine in the treatment of premature ejaculation].
abstract: OBJECTIVE
  To evaluate the clinical effect and safety of dapoxetine in the treatment of premature ejaculation (PE).
  
  
  METHODS
  We randomly assigned 116 PE patients to receive dapoxetine on demand at 30 mg qd (dapoxetine group, n = 60, aged 23-49 years) or oral tamsulosin at 20 mg qd (control group, n = 56, aged 24-46 years). After 4 weeks of medication, we compared the clinical global impression of change (CGIC) , PE profile (PEP) scores, intravaginal ejaculation latency time (IELT) , and adverse reactions between the two groups of patients.
  
  
  RESULTS
  Compared with the baseline, the IELT was remarkably prolonged after treatment both in the dapoxetine group ([0.86 ± 0.17] vs [4.32 ± 2.23] min, P < 0.05) and the control ([0.88 ± 0.15] vs [4.17 ± 2.26] min, P < 0.05), with no statistically significant difference between the two groups (P > 0. 05). The post-treatment rate of CGIC in the dapoxetine group had no statistically significant difference from that in the control (85.00% vs 82.14%, P > 0.05). In comparison with pre-treatment, the patients of both the dapoxetine and control groups showed dramatically improved scores after medication in perceived control over ejaculation (0.85 ± 0.23 vs 2.13 ± 0.97 and 0.88 ± 0.21 vs 2.06 ± 0.34, both P < 0.05), ejaculation-related personal distress (1.15 ± 0.64 vs 2.89 ± 0.26 and 1.19 ± 0.53 vs 2.82 ± 0.69, both P < 0.05), satisfaction with sexual intercourse (0.81 ± 0.33 vs 2.58 ± 0.37 and 0.79 ± 0.28 vs 2.45 ± 0.32, both P < 0.05), and ejaculation-related interpersonal difficulty (2.05 ± 0.61 vs 3.24 ± 0.35 and 2.03 ± 0.65 vs 3.18 ± 0.76, both P < 0.05), with no significant differences between the two groups (P > 0.05). The incidence of adverse reactions was significantly lower in the dapoxetine than in the control group (3.33% vs 30.36%, P < 0.05).
  
  
  CONCLUSIONS
  Dapoxetine is effective for the treatment of PE, with its advantages of prolonging the intravaginal ejaculation latency time, improving the quality of sexual life, and low incidence of adverse reactions.
authors.forename: Xiao-yu
authors.initials: XY
authors.lastname: Chen
authors.forename: Ying-wei
authors.initials: YW
authors.lastname: Qu
authors.forename: Suo-gang
authors.initials: SG
authors.lastname: Wang
mesh_terms: D000328:Adult; D001596:Benzylamines / Q000008:administration & dosage* / Q000627:therapeutic use; D003075:Coitus; D004311:Double-Blind Method; D004542:Ejaculation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000008:administration & dosage* / Q000627:therapeutic use; D017060:Patient Satisfaction; D061686:Premature Ejaculation / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012725:Sexual Behavior; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D000077409:Tamsulosin; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001596:Benzylamines; D009281:Naphthalenes; D017367:Selective Serotonin Reuptake Inhibitors; D013449:Sulfonamides; D000077409:Tamsulosin; C080598:dapoxetine